Full history for every metric is available with a Kvantra account
Sientra, Inc. (SIEN)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 37 | 68 | 84 | 55 | 81 | 91 | 90 |
| Operating profit | $m | -69 | -52 | |||||
| Net profit | $m | -64 | -83 | -107 | -90 | -63 | -73 | -60 |
| EPS reported | $ | -10.27 | -5.95 | |||||
| Operating cashflow per share | $ | -4.92 | -4.92 | |||||
| Capex per share | $ | 0.50 | 0.50 | |||||
| FCF per share | $ | -5.42 | -5.42 | |||||
| Free cash flow | $m | -39 | -15 | |||||
| Net debt | $m | 37 | 44 | |||||
| Book value equity | $m | -1 | - | |||||
| Book value per share | $ | -0.11 | - | |||||
| Number of shares | m | 7.18 | 11.29 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -17.71 | -1.52 | |||||
| P/S LTM | x | 0.16 | 0.02 | |||||
| P/FCF LTM | x | -0.37 | -0.14 | |||||
| EV/EBITDA LTM | x | -0.90 | -1.10 | |||||
| EV/Sales LTM | x | 0.57 | 0.51 | |||||
| Earnings Yield LTM | % | -503.44% | -5873.5% | |||||
| FCF Yield | % | -267.00% | -700.70% | |||||
| Quality | ||||||||
| ROE | % | 8918.1% | -366.21% | |||||
| ROIC | % | -89.06% | -89.06% | |||||
| Operating margin | % | -76.26% | -76.26% | |||||
| Gross margin | % | 45.94% | 45.94% | |||||
| FCF/Sales | % | -42.94% | -42.94% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +12.23% | +2.46% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | -0.02% | |||||
| FCF/Debt | x | -0.62 | -0.23 | |||||
| Net Debt/EBITDA | x | -0.65 | -0.65 | |||||
| EBIT/Net interest | x | -7.25 | -7.25 | |||||
| Net debt/market cap | % | 254.71% | 2104.4% | |||||
| Net debt/Equity | x | -45.12 | - | |||||
| Gross debt/equity | x | -76.84 | - | |||||
Company overview
Sientra, Inc. is a global medical aesthetics firm specializing in the development and distribution of a diverse range of aesthetic medical solutions. Its core offerings encompass silicone gel implants, utilized for both breast enhancement and reconstructive surgeries, alongside breast tissue expanders and various scar management solutions. These products are marketed under prominent brands such as Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. Beyond breast-related items, the company's portfolio extends to include products for body sculpting, facial and nasal implants, and saline-filled sizers. Sientra caters to a broad clientele, including hospitals, surgical facilities, plastic surgeons, dermatologists, and other specialized medical practitioners across the United States and internationally. Established in 2003, the enterprise was initially known as Juliet Medical, Inc., before adopting the Sientra, Inc. designation in April 2007. Its corporate headquarters are situated in Santa Barbara, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Sientra, Inc. (SIEN)
Sientra, Inc. is a global medical aesthetics firm specializing in the development and distribution of a diverse range of aesthetic medical solutions. Its core offerings encompass silicone gel implants, utilized for both breast enhancement and reconstructive surgeries, alongside breast tissue expanders and various scar management solutions. These products are marketed under prominent brands such as Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. Beyond breast-related items, the company's portfolio extends to include products for body sculpting, facial and nasal implants, and saline-filled sizers. Sientra caters to a broad clientele, including hospitals, surgical facilities, plastic surgeons, dermatologists, and other specialized medical practitioners across the United States and internationally. Established in 2003, the enterprise was initially known as Juliet Medical, Inc., before adopting the Sientra, Inc. designation in April 2007. Its corporate headquarters are situated in Santa Barbara, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free